Article
Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease.
Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Jan 2022
Chou Ping-Song, Huang Ling-Chun, Hour Tzyh-Chyuan, Yen Chen-Wen, Yang Yuan-Han
Abstract excerpt
BACKGROUND/PURPOSE: Donepezil was approved for the treatment of Alzheimer's disease (AD) but causes variable therapeutic responses. Thus, identifying specific genetic polymorphisms, which can predict a therapeutic response to donepezil, would enable a development of personalized strategy to treatment for patients with AD. The research aimed to exam the impact of the cytochrome P450 2D6 (CYP2D6) single nucleotide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
